Demand on the rise for MR-guided radiotherapy, says new report
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




MRI Homepage

New progress on manganese-based MR contrast agent Enhances tumor similarly to gadolinium but clears better

New study calls for prebiopsy MR scans in prostate cancer assessment Better able to detect cancers that likely require treatment

NIH researchers uncover potential new indication of severe MS Based on dark-rimmed marks on patient brains

Bayer sells MR endorectal coil product line to DxTx Medical Helps image prostate, colorectal, cervix and surrounding pelvic anatomy

Trendy magnetic eyelashes are the latest potential hazard in the MR suite Can cause artifacts, detach during procedures

MR brain scans reveal differences in US personnel formerly stationed in Cuba Incurred from intensely loud noises in homes and hotel rooms

Study advises personalized breast cancer screenings for cancer survivors May benefit from MR alone, rather than MR and mammography

Knitting raises thousands for Scottish MR scanner fundraising campaign Improving access to care in remote Shetland Islands

CT and MR waiting times costing Canadians over $3 billion Need $4.4 billion to update imaging stock, says report

MR and ultrasound biopsies combined can detect prostate cancers, says study Detect up to 33 percent more tumors together

MR-guided radiotherapy is projected to
rise by a compound annual growth rate
of 20 percent through 2028.

Demand on the rise for MR-guided radiotherapy, says new report

by John R. Fischer , Staff Reporter
The MR-guided radiotherapy systems market is projected to rise by a compound annual growth rate of 20 percent through 2028, according to a new research report by market research firm, Fact.MR.

Entitled MRI-guided Radiation Therapy Systems Market Forecast, Trend Analysis & Competition Tracking — Global Review 2018 — 2028, the report perceives the development of advanced technologies in healthcare and medical devices as the primary driver of growth for the $221 million market, which is "likely" to register 31 percent year-over-year growth in 2019.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"According to FMR analysis, precision and accuracy of MR-guided radiation therapy is far greater than the linear accelerators (LINAC)," Sabyasachi Ghosh, healthcare manager at Fact.MR, told HCB News. "Also, the excessive X-ray dosage to patient through linear accelerator (LINAC) systems is a major concern; hence, MR-guided radiation therapy is a more viable option for cancer care. Additionally, MR-guided radiation therapy allows cross-sectional analysis that is not possible on other options."

The rise in demand can also be attributed to the relatively greater benefits of MR-guided radiotherapy, compared to linear accelerators, favorable reimbursement policies and improvements made by leading market players taking part in conferences, trade shows and exhibitions.

The main target of the market will continue to be hospitals, due to ongoing clinical expansion of high-tech procedures such as linear accelerators integrated with MR radiotherapy (Linac MR-RT).

Leading the market is North America, which accounted for 45 percent of sales in such systems in 2018. It is predicted to retain its position due to a rapid rise in the number of cancer patients being treated with radiotherapy in the U.S., as well as increases in the national expenditures for cancer care brought on by the rise in cancer prevalence. Demand here and in other developed markets is strong, and is also growing in developing nations, some of which have become homes to attractive markets for MR-guided radiotherapy solutions.

Leading players in the report are VIEWRAY Technologies and Elekta AB, based on key financials, SWOT analysis, sales footprint, and recent developments. VIEWRAY recently celebrated the use of its technology in treating the 1000th patient with MR-guided radiotherapy at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, home to the first world’s first MRIdian center.

"The center's trailblazing research and cutting-edge treatments have played a big role in the clinical acceptance and growing adoption of MR-guided radiation therapy, which, in turn, has benefited not just the 1,000 cancer patients at Siteman, but many others around the world," said Scott Drake, president and chief executive officer of ViewRay, in a statement.

MRI Homepage

You Must Be Logged In To Post A Comment